CN1471971A - 重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 - Google Patents
重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 Download PDFInfo
- Publication number
- CN1471971A CN1471971A CNA031269346A CN03126934A CN1471971A CN 1471971 A CN1471971 A CN 1471971A CN A031269346 A CNA031269346 A CN A031269346A CN 03126934 A CN03126934 A CN 03126934A CN 1471971 A CN1471971 A CN 1471971A
- Authority
- CN
- China
- Prior art keywords
- stimulating factor
- colony stimulating
- granulocyte colony
- human granulocyte
- myocardial infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 6
- 206010061216 Infarction Diseases 0.000 title description 5
- 230000007574 infarction Effects 0.000 title description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 17
- 230000002107 myocardial effect Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000011443 conventional therapy Methods 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 206010018687 Granulocytopenia Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241001522301 Apogonichthyoides nigripinnis Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用。本发明利用重组人粒细胞集落刺激因子对骨髓干细胞的动员效能，以及人体骨髓干细胞具有向心肌细胞分化的能力，促使人体自身的骨髓干细胞从骨髓随血液循环进入到心肌梗死部位，并进一步分化成为心肌细胞，修复已梗死的心肌组织，因此彻底治愈心肌梗死。本发明方法简单、安全有效、治疗费用低廉，能在包括基层医院在内的各级医疗单位普遍推广应用。
Description
技术领域
本发明涉及重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用。
技术背景
心肌梗死是当今社会上严重危害人类身体健康的一类常见心脏病。人体心肌细胞是最终分化细胞，无分裂增殖的能力，目前临床上用于心肌梗死的常规治疗，包括药物治疗、介入治疗和手术治疗都仅能改善心肌梗死后残存心肌的血液灌注，避免心肌梗塞灶进一步扩大，但不能修复已梗死的心肌组织。心肌梗死的患者经常规治疗后，由于残存心肌数量的减少而导致心脏功能的下降，常常会丧失了劳动能力甚至发生心力衰竭而死亡。因此心肌梗死仍属于不能治愈的疾病之一，也是当今医疗界所面临的一个世界性难题。
开发一种能修复已梗死心肌组织，促进梗死区内心肌细胞再生的药物，是成功解决这一难题的关键。但新药的开发需投入大量的人力、物力和财力，并且从其研发、投产直至其后的临床前试验、临床试验亦需要耗费很长的时间周期，不能很快应用于临床。如能老药新用，就能够节省时间、人力和物力。
重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulatingfactor，rhG-CSF)，是利用基因重组技术生产的人粒细胞集落刺激因子，与天然的人粒细胞集落刺激因子相比，生物活性在体内、外基本一致。重组人粒细胞集落刺激因子的药理作用为：重组人粒细胞集落刺激因子是调节骨髓中粒系造血的主要细胞因子之一，可选择性地作用于粒系造血祖细胞，促进其增殖、分化，并可增加粒系终末分化细胞即外周血中粒细胞的数目与功能。重组人粒细胞集落刺激因子现有的临床适应症有：(1)促进骨髓移植后中性粒细胞计数增加；(2)癌症化疗后引起的中性粒细胞减少症，包括恶性淋巴瘤、小细胞肺癌、胚胎细胞瘤(睾丸肿瘤、卵巢肿瘤等)、神经母细胞瘤等；(3)骨髓增生异常综合征伴发的中性粒细胞减少症；(4)再生障碍性贫血伴发的中性粒细胞减少症；(5)先天性、特发性中性粒细胞减少症(参见：陈新谦，金有豫.新编药物学.第14版.北京：人民卫生出版社，1998.402-403.)。该药已在临床上应用了十余年，经数以千万的病人使用，其毒副作用甚微。
发明内容
本发明的目的是开发出重组人粒细胞集落刺激因子的新用途，即在制备治疗心肌梗死的药物中的应用。
本发明利用重组人粒细胞集落刺激因子对骨髓干细胞的动员效能，以及人体骨髓干细胞具有向心肌细胞分化的能力，促使人体自身的骨髓干细胞从骨髓随血液循环进入到心肌梗死部位，并进一步分化成为心肌细胞，修复已梗死的心肌组织，从而实现了本发明的目的。
本发明的技术特征在于重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用。
心肌梗死患者经常规的心电图以及心肌酶学检查明确诊断后，用重组人粒细胞集落刺激因子剂量250～300μg皮下或静脉或心导管注射，每日1次，共3～7次治疗，疗程结束后可用常规心电图、超声心动图、单电子发射计算机体层摄影(SPECT)心肌灌注和心血池显像等检查，对其治疗效果(包括心肌梗死的范围和心脏功能)做出客观评价。
本发明具有如下优点：
(1)能促进梗死区内心肌细胞再生，修复已梗死的心肌组织，达到目前任何心肌梗死的常规治疗所不能取得的治疗效果，彻底治愈心肌梗死；为了更好地体现本优点，下面将分别用动物实验和临床实验加以说明：
动物试验：用重组人粒细胞集落刺激因子治疗心肌梗死的大鼠20例后，大鼠心肌梗死面积仅占心室肌总面积的(5.6±1.57)％，心肌疤痕面积仅为心室肌总面积的(2.7±0.82)％；而不用重组人粒细胞集落刺激因子治疗，仅用生理盐水处理的对照组20例心肌梗死大鼠的心肌梗死面积占心室肌总面积的(17.3±2.31)％，心肌疤痕面积则为心室肌总面积的(8.8±1.13)％；
临床实验：用心肌梗死常规治疗药物的基础上加用重组人粒细胞集落刺激因子治疗心肌梗死患者13例，患者心肌梗死面积从治疗前占心室肌总面积的(36.9±7.5)％减少至(17.8±6.8)％(P＜0.05)；而只用心肌梗死常规治疗药物治疗心肌梗死患者13例，治疗前患者心肌梗死面积占心室肌总面积的(39.1±8.9)％，治疗后为(38.0±10.0)％，前后无统计学差异；
(2)方法简单、安全有效、治疗费用低廉，能在包括基层医院在内的各级医疗单位普遍推广应用；
(3)老药新用，节省重新研究开发新药所需的大量投入，缩短临床前研究所需时间。
附图说明
图1：
心肌梗死患者用重组人粒细胞集落刺激因子治疗前(A)和治疗后(B)心肌梗死面积变化的极坐标靶心图。
具体实施方式
实施例1：
一名男性心肌梗死患者经常规的心电图以及心肌酶学检查明确诊断后，用重组人粒细胞集落刺激因子剂量300μg皮下注射，每日1次，共4次治疗，疗程结束后可用单电子发射计算机体层摄影(SPECT)心肌灌注显像检查，心肌梗死面积从治疗前占心室肌总面积的33％(见图1A的黑色部分)减少至7％(见图1B的黑色部分)。
Claims (1)
1.重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031269346A CN1471971A (zh) | 2003-06-20 | 2003-06-20 | 重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031269346A CN1471971A (zh) | 2003-06-20 | 2003-06-20 | 重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1471971A true CN1471971A (zh) | 2004-02-04 |
Family
ID=34153146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031269346A Pending CN1471971A (zh) | 2003-06-20 | 2003-06-20 | 重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1471971A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969040B (zh) * | 2004-03-19 | 2014-12-10 | 阿斯特利亚斯生物治疗股份公司 | 制备适合用于再生医学的高纯度心肌细胞的方法 |
-
2003
- 2003-06-20 CN CNA031269346A patent/CN1471971A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969040B (zh) * | 2004-03-19 | 2014-12-10 | 阿斯特利亚斯生物治疗股份公司 | 制备适合用于再生医学的高纯度心肌细胞的方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure | |
| Duggal et al. | Regional blood flow during closed-chest cardiac resuscitation in rats | |
| Grimm et al. | Cardiopulmonary effects of fentanyl in conscious dogs and dogs sedated with a continuous rate infusion of medetomidine | |
| CN103126866B (zh) | 癌症扩散转移治疗器 | |
| Mallesch et al. | The pharmacokinetics of p-boronophenylalanine. fructose in human patients with glioma and metastatic melanoma | |
| Warrell et al. | Giant-cell arteritis with peripheral neuropathy | |
| Farzamfar et al. | Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs | |
| Swedberg et al. | Heart Failure as Complication of Lithium Treatment: Preliminary Report of a Fatal Case | |
| TW200833345A (en) | Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues | |
| Knox et al. | Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy | |
| CN1471971A (zh) | 重组人粒细胞集落刺激因子在制备治疗心肌梗死的药物中的应用 | |
| Ahn et al. | The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer | |
| CN101528251A (zh) | 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂 | |
| CN103041411A (zh) | 以磷脂酰丝氨酸为靶点的99Tcm-Cys-AnnexinV标记化合物及其标记技术和应用 | |
| Robins et al. | A pilot study of melphalan, tumor necrosis factor-α and 41.8° C whole-body hyperthermia | |
| CA1295243C (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| Zhou et al. | The efficacy of high-intensity, focused ultrasound treatment for non-neoplastic epithelial disorders of the vulva | |
| Shank et al. | The role of total body irradiation in bone marrow transplantation for leukemia. | |
| CN105330749B (zh) | 放疗增敏融合多肽的构建及应用 | |
| Burke et al. | The correlation of maximal drug dose, tumor recruitment, and sequence timing with therapeutic advantage: Schedule‐dependent toxicity of cytosine arabinoside | |
| CN205084002U (zh) | 一种用于人体俞穴和耳穴的揿针磁性载药贴 | |
| CN1589904A (zh) | 造血干细胞动员剂制备治疗糖尿病药物的用途 | |
| Mishra et al. | Diel rhythmicity of certain life events of a ladybird, Propylea dissecta (Mulsant) | |
| Somogyi et al. | Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor | |
| Tanigaki et al. | A case of squamous cell carcinoma treated by intralesional injection of oil bleomycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |